Trial Profile
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Mitomycin (Primary) ; Pegfilgrastim (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 29 Jan 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
- 10 Aug 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2023.
- 21 Jun 2022 Status changed from recruiting to active, no longer recruiting.